The trend we have noted previously in the decline in the number of pharma M&A deals continues this month. If a deal is to be done it is more likely to be a licensing transaction. In September, the majority of deals were licences and there were more acquisitions of specific assets than company acquisitions. Those companies that need to raise cash, for example Teva to tackle its debt crisis, continue to announce asset divestments.
|Deal Type||Headline ($m)|
|Licence, collaboration, option||1,865|
|Teva Pharmaceutical Industries
|Acquisition - asset||1,100|
|Acquisition - asset||766|
CVC Capital Partners
|Acquisition - asset||703|
Foundation Consumer Healthcare
|Acquisition - asset||675|
|Click here to view the top 20 deals for September|
The full report also contains:
- The top 20 deals of the month
- The spin out - the deal du jour?
- Regional deals with a Chinese twist
- Allergan goes tribal
- Pricing pressures
Want to read the complete report?
Interested in reading the past issues?